CURA Diagnostics Acquires Transversal Therapeutics – Will Offer Innovative Sensor Technologies for Point-of-Care Devices

Greater Boston Area, June 16, 2023 - In a groundbreaking move set to transform the landscape of point-of-care diagnostics, CURA Diagnostics has acquired Transversal Therapeutics. Transversal is a pioneering force in the field of sensor technologies, developing state-of-the-art solutions designed to enhance diagnostic accuracy and speed. Their groundbreaking nano-biosensors, meticulously crafted through years of research and innovation, have garnered widespread recognition for their precision and reliability.

By combining the expertise at CURA and Transversal, the two entities are poised to revolutionize point-of-care diagnostics and CURA solidifies its position as an industry leader in the diagnostic marketplace. The integration of Transversal's sensor technologies into the point-of-care devices will empower healthcare professionals to make rapid, informed decisions in their clinic or office, facilitating effective treatment planning and ultimately improving patient outcomes.

As stated by CURA’s CEO, Jia He: “CURA Diagnostics now has access to Transversal's cutting-edge technology, which will play a pivotal role in enhancing our point-of-care diagnostic tests.” By integrating these advanced sensors into their existing diagnostic tests, the company aims to significantly enhance the accuracy, efficiency, and reliability of point-of-care diagnostics.  “We believe that this development will have a profound and positive impact on the standard of care in our field, ultimately benefiting patients worldwide.”

【Read more】